Purpose: The clinical features of autoimmune retinopathy (AIR) can resemble and be difficult to differentiate from inherited retinal degenerations (IRDs). Misdiagnosis of an IRD as AIR causes unnecessary treatment with immunosuppressive agents. The purpose of this study is to calculate the predictive value of genetic testing for IRDs in patients with suspected AIR and provide clinical examples where genetic testing has been useful. Methods: We identified patients seen at MEEI between April 2013 and January 2017 for whom the differentiation of AIR vs. IRDs was difficult based on clinical assessment alone. All patients had some atypical features for AIR, but tested positive for anti-retinal antibodies. Within this group, we identified six patients who had genetic testing for IRDs with the Genetic Eye Disease panel for retinal genes (GEDi-R). We calculated the positive predictive value (PPV) and negative predictive value (NPV) of genetic testing in a population with approximately equal numbers of IRD and AIR patients. Results: Six patients had clinical features that made distinguishing between IRDs and AIR on a clinical basis difficult and were sent for genetic testing: four women and two men with a mean age of 59.5 years. In two of these six patients, genetic diagnoses were made based upon the identification of known pathogenic variants in the common IRD genes USH2A and RHO. Two patients had variants of unknown significance within genes associated with IRDs, and the other two had no relevant genetic findings. Given the 60% sensitivity and 3% false positive rate for GEDi-R testing and assuming a 50% pre-test probability of having an IRD, the PPV for GEDi-R for detecting IRD is 95.2% and the NPV is 70.8%. Conclusions and Importance: In patients for whom the differential diagnosis of AIR and IRDs is unclear based on clinical information, genetic testing can be a valuable tool when it identifies an IRD, sparing the patient unnecessary immunosuppressive treatment. However, the test has a low NPV so a negative genetic testing result does not confidently exclude IRD as the true diagnosis.
Introduction
Autoimmune retinopathy (AIR) is a rare blinding retinal disorder characterized by the presence of antiretinal autoantibodies (ARAs), electroretinogram (ERG) abnormalities, and visual field defects. 1 The spectrum of AIR includes nonparaneoplastic AIR (npAIR), cancer-associated retinopathy (CAR), melanoma-associated retinopathy (MAR), and autoimmune-related retinopathy and optic neuropathy (AARON). Though the exact pathogenesis of AIR is not known, AIR is thought to be the result of an immunologic attack on the retina by ARAs causing damage to ocular tissues resulting in vision loss. [2] [3] [4] The presence of ARAs is an essential criterion for the diagnosis of AIR. However, ARAs can also be present in patients with other autoimmune disorders as well as in normal controls. 5 Due to the low specificity of ARAs and lack of distinctive clinical features, the diagnosis of AIR is usually made after the exclusion of inherited retinal degenerations (IRDs) and other retinal degenerative disorders. 1 However, the differentiation between of IRDs and AIR is not always clear. IRDs are a phenotypically diverse set of diseases that affect the function of photoreceptors and the retinal pigment epithelium (RPE). 6 Retinitis pigmentosa (RP) is the most common IRD, and its clinical characteristics are particularly similar to those of AIR. 7 There are some clinical features which help differentiate these two diagnoses. A typical AIR patient will be older than the average IRD patient. AIR tends to present with sudden or subacute vision loss while more slowly progressive vision loss is usually seen in IRDs. AIR patients often have a relatively normal retinal examination, especially at disease onset. examination as well as abnormalities in retinal imaging. IRD patients sometimes, but not always, have a family history of retinal disease. Further complicating the issue, reports of patients with hereditary RP developing secondary ARAs have been published. 8, 9 As the treatments for AIR and IRDs vary greatly, the difficulty in clinically differentiating between these diagnoses can greatly impact patient outcomes. For example, the misdiagnosis of an IRD as AIR causes unnecessary treatment with immunosuppressive agents. Side effects of immunosuppressive agents include an increased risk of infections. In a study of 30 AIR patients, 10% of the patients had to stop at least one immunosuppressive medication due to adverse effects. 10 Distinguishing IRD patients from potential AIR patients is essential to setting patient outcome expectations, providing risk assessment to family members, administering proper treatment, and preventing unnecessary side effects from treatment.
A potential way to differentiate atypical AIR presentations from IRDs is through genetic testing; there are currently over 250 genes known to cause IRDs. 11 Genetic testing for IRDs currently has a 50-60% sensitivity, with some testing achieving a sensitivity of more than 75% when using a clinically directed tiered testing strategy. 12 A previous study has shown insight into the utility of genetic testing in distinguishing between IRDs, 13 however no study has examined its utility in differentiation between IRDs and AIR. In this retrospective case series, we examine the utility of genetic testing in distinguishing AIR from IRDs and providing a more accurate diagnosis that could spare patients unnecessary treatment with immunosuppressive therapy. We calculate the predictive value of genetic testing for IRDs in patients with suspected AIR and provide productive examples of this testing in clinical practice.
Methods
This retrospective case series was approved by the Massachusetts Eye and Ear Infirmary (MEEI) institutional review board. The study conformed to the tenets of the Declaration of Helsinki and HIPAA regulations.
We identified patients evaluated on both the Ocular Immunology and IRD Services at MEEI between April 2013 and January 2017 for whom the differentiation of AIR vs. IRD was questioned based on clinical assessment alone. We further identified the subset of these patients who had genetic testing for IRDs. All patients had some atypical features for AIR but tested positive for ARAs. The following data was collected for each patient: age at presentation, sex, clinical findings, visual acuity (VA), fundus photo interpretations, fluorescein angiography (FA) interpretations, full-field ERG results, optical coherence tomography (OCT) results, Goldmann Visual Field (GVF) results and ARAs, closest to the date of blood draw for genetic testing.
The best corrected VA, with correction by pinhole when applicable, was recorded. Full-field ERGs were performed with Burian-Allen electrodes (Hansen Labs, Coralville, Iowa, USA) at MEEI. Dim scotopic, bright scotopic, 30 Hz flicker amplitudes, and 30 Hz flicker implicit times were obtained. OCT imaging was performed with a spectral domain OCT instrument (Spectralis, Heidelberg, Germany). Fovea-centered images were acquired (25 lines within a 20-degree horizontal scan and 25 lines within a 20-degree vertical scan). GVF testing with I2e, I4e, and V4e test lights was performed. ARA testing was done by Western blot either at the Ocular Immunology Laboratory, Casey Eye Institute, Oregon Health Sciences University (Patients 1, 4, 5 and 6) or at the University of Michigan Medical School (Patients 2 and 3).
Genetic testing performed at The Ocular Genomic Institute at MEEI with Genetic Eye Disease panel for Retinal genes (GEDi-R) using nextgeneration sequencing.
14 It is performed by selective capture of exon, splice sites and specific intronic variants for 267 genes associated with IRDs. A list of genes analyzed by GEDi-R can be found in Table 1 .
Variants were annotated using a custom human base-pair codon resource. Variant interpretation was performed according to American
College of Medical Genetics practice guidelines. [15] [16] [17] GEDi-R testing has a 60% clinical sensitivity in patients with IRDs and a false positive rate of approximately 3%. 14 We calculated the positive predictive value (PPV) and negative predictive value (NPV) of genetic testing assuming a 33%, 50%, and 66% prevalence of IRDs in the population using standard formulas. 18 The determination of the range of IRD prevalences was based on the clinical experience of the physician authors since there is a lack of data in the literature regarding this topic.
Results
Six patients with clinical features making differentiation between IRDs and AIR difficult underwent genetic testing: four women and two men with a mean age of 59.5 years. These patients presented with clinical features typical for both AIR and IRD, making the diagnosis difficult. For example, there may have been fundus findings atypical for but potentially consistent with an IRD in a middle-aged patient without a family history of retinal disease. Clinical characteristics of these six patients can be found in Table 2 . In two of these six patients, genetic diagnoses were made based upon the identification of known pathogenic variants in the common IRD genes: USH2A [c.2299delG (p.Glu767Serfs) and c.2276G > T (p.Cys759Phe)] and RHO [c.745G > T (p.Glu249Ter)]. Genetic diagnoses were not identified for the other four patients. Table 3 shows the GEDi-R results, along with the ARA results and final diagnosis of each patient.
Pathogenic variants in IRD-causing genes were identified in patients GT-01 and GT-02 (see Table 3 ). Color fundus photos, fundus autofluorescence (FAF) photos, and OCT images of the central macula for patient GT-01 can be found in Fig. 1 . The differential diagnosis for GT-01 included AIR vs. RP. This patient first presented with photopsias and initial visual fields suggesting acute idiopathic big blind spot syndrome versus acute zonal occult outer retinopathy. Over several years, pericentral scotomas developed subjectively as well as on perimetry and were accompanied by nyctalopia. Multi-focal and full-field ERGs were suggestive of mild macular and panretinal photoreceptor degeneration. The full-field ERG pattern was atypically mild for RP: 50% decrease in scotopic amplitudes and normal 30 Hz amplitudes but prolonged implicit times. The FAF and OCT imaging demonstrated symmetric findings that, in combination with her ERGs, could be pericentral RP; however, the possibility of AIR was also raised. Taking into account the lack of family history of retinal disease and positive ARAs which included enolase, a common antibody found in patients with AIR, 19 the diagnosis of GT-01 was ambiguous. GEDi-R testing revealed compound heterozygous recessive pathogenic mutations in the USH2A gene with parental segregation. Mutations in USH2A are known to cause autosomal recessive Usher syndrome as well as non-syndromic RP. Color fundus photos, FAF, and OCT images of the central macula for patient GT-02 can be found in Fig. 2 . GT-02 initially presented with photopsias. Further testing revealed slight superior GVF constriction as well as decreased cone and rod responses with a slight delay in implicit times on full-field ERG testing. GT-02 had a history of cutaneous squamous cell carcinoma and pulmonary nodules making CAR a possibility, particularly given his age at presentation. He tested positive for several ARAs and had no family history of IRDs, however, his symptoms were very slowly progressive for AIR and warranted further investigation. Genetic testing identified a heterozygous pathogenic mutation in RHO. In the absence of familial clinical data or genetic samples, it remained unclear whether this was a de novo mutation or if it was associated with a mild and undetected phenotype in other family members.
The genetic testing for the remaining four patients was inconclusive. GT-03 was a 59-year old Asian female was thought to have AIR based on clinical features including inner retinal thinning. Of note, family history was significant for two siblings with congenital hearing loss but no reported vision loss. Genetic testing did not identify a clear genetic diagnosis. Testing did identify variants of unknown significance (VUSs) in two genes known to cause autosomal recessive Usher syndrome (USH1C and USH2A; Table 3 ). Two additional VUSs were found genes associated with IRDs (EYS and SLC24A1; Table 3 ).
GT-04 presented with photopsia of the left eye. Upon examination she had visual field loss, pigmentary features typical of RP, and an extinguished full-field ERG in the left eye. The right eye was normal. She further developed night blindness and floaters. Initially, she was thought to have unilateral late onset RP, although unilateral presentation of RP is very rare. About two years later, she began to exhibit visual field constriction and ERG revealed marked attenuation of right eye retinal function. At this point, rapid progression of her disease was thought to be unusually fast for RP and AIR was considered in the differential diagnosis. ARAs were detected in her serum, and GEDi-R testing was negative in this patient.
GT-05 presented with symptoms indicative of AIR including glare at night, decreased color vision, and large central scotomas. She had a normal rod responses and low normal cone responses on ERG. Medical history was significant for Crohn's disease and breast cancer. FAF results showed a speckled bull's eye pattern of pigment loss which is atypical in AIR patients. ARAs were detected. Genetic testing, however, did not identify any pathogenic variants but did identify two VUSs in two genes known to cause IRDs (CEP290 and MERTK; Table 3 ).
GT-06 presented with an inability to see in bright lights, trouble looking at objects against a white background, and "black and white throbbing spots." Upon examination he was found to have bilateral central scotomas, sub-normal vision, abnormal multi-focal ERG, and reduced and delayed full-field ERG responses. It was thought his clinical symptoms were consistent with a rod-cone dystrophy such as RP, but the clinical picture was atypical given preferential central versus peripheral retinal involvement. The progression of disease was also more rapid than normally seen in RP patients and as a result he was sent for GEDi-R testing which was negative. ARAs were detected in his serum.
For the purposes of calculating PPV and NPV, we roughly estimated that in the cohort of patients used in this study, the prevalence of IRD was 50%, before genetic testing. Given the 60% sensitivity and 3% false positive rate of GEDi-R testing, we calculated the PPV of genetic testing to be 95.2% and the NPV to be 70.8%. Different clinicians might produce a cohort leaning more toward one diagnosis or the other. Table 4 demonstrates how the predictive value changes in higher-or lowerprobability cohorts/patients. These calculations rely only on the equations defining sensitivity and specificity and the known characteristics of the genetic test, rather than using any data explicitly from our cohort. If a similar population with an estimated 33% IRD incidence were tested in the future, the PPV and NPV would be 90.8% and 83.1%, respectively. In a population with 66% estimated prevalence of IRD, the PPV and NPV would be 97.5% and 55.5%, respectively.
Discussion
The results in Table 4 demonstrate that when IRD genetic testing is performed in a patient population with a moderate chance of having a genetic disease, such as our patient population, a positive genetic finding helps "rule in" a genetic disease, but a negative result does not "rule out" a genetic disease. In fact, Table 4 shows that this finding holds true over a range of clinical scenarios where a patient is more or less likely to have a genetic diagnosis before testing. This is a natural consequence of the imperfect sensitivity of the current genetic testing for IRDs (50-60% diagnostic rate).
14 Another collection of patients may have different pre-genetic testing probabilities of having an IRD, based on the criteria used to assemble the cohort. For that reason, we provided PPV and NPV calculations for a variety of pre-test probabilities. With progress in diagnostics, more disease-causing variants in both known and undiscovered genes will be found, and the sensitivity and therefore the predictive value of genetic testing will increase. Similarly, the diagnostic testing for AIR (e.g. ARA testing) is imperfect in positively identifying AIR patients, and improvements in this testing would be very helpful as well.
20,21
The diagnosis of a genetic disorder not only avoids use of potentially ineffective anti-inflammatory or immunomodulatory therapies but also can provide risk information for other family members as well as potentially providing eligibility for gene-based therapies. As a result of our findings, we were able to definitely diagnose two patients with an IRD thus sparing them immunosuppressive therapy. All the patients in this series whose genetic results were equivocal or negative were treated for AIR with immunosuppression and counseled that there was still a small chance they have a genetic cause of their disease that we could not identify and that their exposure to immunosuppressive therapy would not be beneficial and could be potentially harmful. This point is controversial; there are published reports of AIR coexisting with IRD, and some clinicians have advocated immunosuppressing patients in this situation. 8, 10 The cases with genetic diagnoses are reminders of the spectrum of severity with which IRDs can manifest. Table 1 The 267 genes analyzed using GEDi-R. All known isoform of the tabulated genes described below have been accounted for in this design. Whole mitochondrial genome sequencing is performed with this panel. BBS5  CERKL  DHX38  GRM6  JAG1  MVK  PCDH15  PRCD  RLBP1  TEAD1  UNC119  ABCC6  BBS7  CHM  DRAM2  GRN  KCNJ13  MYO7A  PCYT1A  PRDM13  ROM1  TEK  USH1C  ABHD12  BBS9  CIB2  DTHD1  GUCA1A  KCNV2  NDP  PDE6A  PROM1  RP1  TIMM8A  USH1G  ACBD5  BEST1  CLN3  EFEMP1  GUCA1B  KCTD7  NEK2  PDE6B  PRPF3  RP1L1  TIMP3  USH2A  ADAM9  C1QTNF5  CLN5  ELOVL4  GUCY2D  KIAA1549  NEUROD1  PDE6C  PRPF31  RP2  TMEM126A  VCAN  ADAMTS18  C21orf2  CLN6  EMC1  HARS  KIF11  NMNAT1  PDE6G  PRPF4  RP9  TMEM231  VPS13B  AFG3L2  C2ORF71  CLN8  ERCC6  HMX1  KIZ  NPHP1  PDE6H  PRPF6  RPE65  TMEM237  WDPCP  AHI1  C5orf42  CLRN1  EYS  IDH3B  KLHL7  NPHP3  PDZD7  PRPF8  RPGR  TMEM67  WDR19  AIPL1  C8orf37  CNGA1  FAM161A  IFT122  LCA5  NPHP4  PEX1  PRPH2  RPGRIP1  TOPORS  WDR34  ALMS1  CA4  CNGA3  FLVCR1  IFT140  LRAT  NR2E3  PEX10  RAB28  RPGRIP1L  TPP1  WDR35  ARL13B  CABP4  CNGB1  FOXF2  IFT172  LRIT3  NRL  PEX14  RAX2  RS1  TREX1  WFS1  ARL2BP  CACNA1F  CNGB3  FSCN2  IFT27  LRP5  NYX  PEX16  RBP3  SAG  TRIM32  ZNF408  ARL6  CACNA2D4  CNNM4  FZD4  IFT43  LZTFL1  OAT  PEX19  RBP4  SDCCAG8  TRPM1  ZNF423  ASRGL1  CAPN5  COL11A1  GDF6  IFT80  MAK  OCA2  PEX2  RCBTB1  SEMA4A  TSPAN12  ZNF513  ATF6  CC2D2A  COL2A1  GNAT1  IFT88  MAPKAPK3  OFD1  PEX5  RD3  SLC24A1  TTC21B  ATXN7  CDH23  COL9A1  GNAT2  IKBKG  MERTK  OPA1  PEX6  RDH12  SLC25A46  TTC8  BBIP1  CDH3  CRB1  GNB1  IMPDH1  MFN2  OPA3  PEX7  RDH5  SLC45A2  TTLL5  BBIP1  CDHR1  CRX  GNPTG  IMPG1  MFRP  OPN1LW  PHYH  REEP6  SLC4A5  TTPA  BBS1  CEP164  CSPP1  GPR125  IMPG2  MFSD8  OPN1MW  PITPNM3  RGR  SLC7A14  TUB  BBS10  CEP290  CSPP1  GPR143  INPP5E  MIR204  OPN1SW  PLA2G5  RGS9  SNRNP200  TUBGCP4  BBS12  CEP41  CYP4V2  GPR179  INVS  MKKS  OTX2  PNPLA6  RGS9BP  SPATA7  TULP1  BBS2  CEP78  DFNB31  GPR98  IQCB1  MKS1  PANK2  POC1B  RHO  SPP2  TYR  BBS4  CEP83  DHDDS  GRK1  ITM2B  MTTP  PAX2  PPT1  RIMS1  SRD5A3  TYRP1 L.K. Stanwyck, et al. Table 3 Results of GEDi-R genetic testing for IRDs, ARA testing, and final diagnosis of all patients in the study. 
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Application to our cohort
In six patients who had a differential diagnosis of AIR vs. IRD, two had genetically confirmed diagnosis of an IRD and four had no genetic diagnoses. While the emphasis of this report is on the use of genetic testing to distinguish IRD from AIR, it is also important to apply the diagnostic criteria 1 for these disorders clinically before considering ARA and/or genetic testing. Proper application of the criteria can point towards the correct diagnoses, thus avoiding unnecessary blood testing. For example, FAF findings consistent with an IRD could lead the clinician away from an AIR diagnosis and preclude need for ARA testing. The known IRD mutations found in our patients were found in the genes RHO and USH2A. GT-01 had compound heterozygous mutations in USH2A which were confirmed to be bi-parentally inherited. USH2A encodes Usherin, a protein found in the basement membrane and thought to be important in the development and homeostasis of the inner ear and retina. 22 The two USH2A mutations identified in GT-01 are among the most common mutations in USH2A-related retinal disease. While USH2A-associated vision loss usually progresses to a greater degree by adulthood than what was observed in this patient, mutations in the USH2A gene can display a wide phenotypic spectrum as exemplified by this patient and potentially lead to the overlap with an AIR-like presentation. 23 The second patient with positive genetic testing, GT-02, had a single heterozygous mutation in the gene RHO. RHO encodes rhodopsin, a photosensitive protein found exclusively in rod cells. 24 While mutations in RHO are associated with autosomal dominant RP, mutations in this gene can also cause autosomal recessive disease. The c.745G > T mutation identified in our patient has been reported to cause autosomal recessive RP. 25 Rosenfeld et al. reported that while heterozygous carriers of this variant had a normal ophthalmologic exams, ERG testing demonstrated decrease rod signals. 25 This may explain the mild nature of symptoms in patient GT-02. In addition to the pathogenic mutations identified in our cohort, seven heterozygous VUSs were identified across seven genes. 17 None of these seven variants, which all occurred in genes associated with autosomal recessive inheritance, were accompanied by a second variant in the same gene. It is not uncommon for patients with no ocular disease to have a number of VUSs. 26 In conclusion, genetic testing can be a valuable tool when it identifies an IRD in a patient for whom the differential diagnosis of AIR versus IRD is unclear based only on clinical information, thus sparing the patient unnecessary treatment with immunosuppressive agents. However, the test has a low NPV, meaning that a negative genetic testing result does not confidently exclude IRD as the true diagnosis. We presented cases demonstrating how IRD genetic testing can be successfully utilized in a patient population with moderate risk of IRD.
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